ClinicalTrials.gg
RecruitingNCT06854367ACT-LLDUpdated Oct 22, 2026

Accelerated vs. Conventional Theta Burst Stimulation for Late-life Depression

An interventional study of TBS in Late Life Depression (LLD), Depression - Major Depressive Disorder and Depressive Disorder, Treatment-Resistant, sponsored by Centre for Addiction and Mental Health. Recruiting at 2 sites in Canada. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health — 4 open to participants now, 5 under way, none of them phase 3. Depressive Disorder, Treatment-Resistant · Centre for Addiction and Mental Health.

Planned enrollment
Largest of 15
280 · median 40
Started
2025
with 2 others
No phase
8 of 15
1 open now
Registered
14th of 15
by date

Among the 15 studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health, this one has the largest planned enrollment, is one of 3 that started in 2025, is one of 8 with no phase, and was the 14th registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

4 of the 15 studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health, or all of them as a file.
02

Study summary

The purpose of this trial is to compare the treatment efficacy (improvement in depressive symptoms) of accelerated TBS protocol (where participants receive multiple TBS treatments daily) to conventional TBS protocol (where participants receive a single TBS treatment daily) in late life depression. In addition, the study also aims to determine if specific patterns of stimulation are more or less effective. To do this, all participants will receive active treatments, but some of the participants in this study will receive accelerated TBS and some will receive once daily TBS.

Read the detailed description

The purpose of this trial is to compare the treatment efficacy (change in MADRS scores) of accelerated TBS to conventional TBS in participants with moderate to severe LLD at 4-weeks following accelerated TBS or following 30 once daily treatments of conventional TBS. Accelerated TBS group will receive 5 treatment sessions per day at approximately 1 hour intervals for 4 consecutive days on week 1 and 2 non-consecutive days on week 2. Conventional TBS group will receive 30 once daily treatment (approximately 6 weeks). Each treatment will consist of either 1) cTBS of right DLPFC followed by iTBS of left DLPFC; or 2) iTBS of left DLPFC.

03

Conditions studied

  • Late Life Depression (LLD)
  • Depression - Major Depressive Disorder
  • Depressive Disorder, Treatment-Resistant
  • Mood Disorders

Keywords

  • Brain stimulation
  • rTMS
  • Theta burst stimulation
  • Accelerated theta burst stimulation
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. are voluntary and competent to consent to treatment
  2. are an outpatient
  3. are ≥ 60 years old
  4. have a Mini International Neuropsychiatric Interview (MINI 7.0) confirmed diagnosis of MDD, with a current MDE
  5. have failed to achieve a clinical response to an adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of ≥ 3 in the current episode or have failed to tolerate two separate trials of an antidepressant
  6. have a score ≥ 10 on the Patient Health Questionnaire (PHQ-9)
  7. have had no increase or initiation of any antidepressant or antipsychotic medication in the 4 weeks prior to screening
  8. are able to adhere to the treatment schedule
  9. pass the TMS adult safety screening (TASS) questionnaire

Exclusion criteria

Exclusion Criteria:

  1. have a Mini International Neuropsychiatric Interview (MINI 7.0) confirmed diagnosis of substance dependence or abuse within the last 3 months
  2. have a concomitant major unstable medical illness as determined by one of the study physicians
  3. have active suicidal intent
  4. have presumed or probable dementia or clinical evidence of dementia as assessed by Short Blessed Test score ≥ 10
  5. have a lifetime MINI diagnosis of bipolar I or II disorder, or primary psychotic disorder
  6. have current psychotic symptoms
  7. have a diagnosis of obsessive compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), or dysthymia, assessed by a study investigator to be primary and causing greater impairment than MDD
  8. have a diagnosis of any personality disorder as assessed by a study investigator to be primary and causing greater impairment than MDD
  9. did not respond to a course of ECT in the current depressive episode
  10. have received rTMS in the current episode; patients who have had rTMS in a previous episode would be eligible
  11. have a history of a primary seizure disorder or a seizure associated with an intracranial lesion
  12. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed
  13. have an implanted electronic device that is currently in function such as a defibrillator
  14. have a non-correctable sensory impairment (i.e., cannot hear well enough to cooperate with interview)
  15. have clinically significant laboratory abnormality, in the opinion of a study investigator
  16. currently take more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant
  17. if participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Active comparator
    Accelerated TBS

    Multiple treatments a day (5 treatments/day) for 4 consecutive days in the first week and 2 non-consecutive days in the second week.

    Device: TBS

  • Active comparator
    Conventional TBS

    Treatment once a day for 30 days (e.g., 5 days a week for 6 weeks)

    Device: TBS

Interventions

  • DeviceTBS

    Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive neurostimulation that uses focused magnetic field pulses to directly stimulate cortical neurons. Theta burst stimulation (TBS) is a briefer form of patterned rTMS that has been shown to be effective against major depressive disorder. Each treatment will consist of either 1) cTBS of right DLPFC followed by iTBS of left DLPFC; or 2) iTBS of left DLPFC.

06

What researchers measure

Primary outcomes

  1. Depression severity

    Montgomery Asberg Depression Rating Scale (MADRS) Change

    Time frame: 6 weeks

Secondary outcomes

  1. Depression severity

    17 item Hamilton Depression Rating Scale (HDRS-17) Change

    Time frame: up to 10 weeks

  2. Depression severity

    The Beck Depression Inventory (BDI-II) Change

    Time frame: up to 10 weeks

  3. Anxiety severity

    General Anxiety Disorder-7 (GAD-7) Change

    Time frame: up to 10 weeks

  4. Suicidal ideation

    The Beck Scale for Suicide Ideation (BSS) Change

    Time frame: up to 10 weeks

  5. Global cognition

    Montreal Cognitive Assessment (MoCA) Change

    Time frame: up to 10 weeks

  6. Executive function

    Delis-Kaplan Executive Function System (D-KEFS) Change

    Time frame: up to 10 weeks

  7. Executive function

    NIH Toolbox Flanker Inhibitory Control and Attention Test

    Time frame: up to 10 weeks

  8. Memory

    California Verbal Learning Test- third edition (CVLT-3) Change

    Time frame: up to 10 weeks

  9. Disability and Functional Impairment

    Sheehan Disability Scale (SDS) Change

    Time frame: up to 10 weeks

  10. Quality of Life Measure

    Quality of Life Enjoyment and Satisfaction Scale (Q-LES-Q) change

    Time frame: up to 10 weeks

  11. Quality of Life Measure

    World Health Organization Quality of Life Short Version (WHOQOL-BREF) Change

    Time frame: up to 10 weeks

  12. Participant Expectancy of Improvement and Preference

    Modified Stanford Expectations of Treatment Scale (SETS)

    Time frame: Baseline

07

Study locations

2 of 2 sites recruiting
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
  • Centre for Addiction and Mental Healh
    Toronto, Ontario M6J 1H1, Canada
    Recruiting
    • Elizabeth Clancy · Contactelizabeth.clancy@camh.ca · 416-535-8501
    • Hyewon (Helen) Lee · Principal investigator
    • Daniel Blumberger · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Nov 2029, 56 months after the start.

Of 136 non-industry interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 56 months is above that.

Counting every sponsor, half of 140 studies reached it within 50 months; a quarter within 22 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Mar 3, 2025
StartActual
Mar 27, 2025
Primary completionEst.
Nov 2029
CompletionEst.
Dec 2029
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06854367
Responsible party
Sponsor
First posted
Mar 3, 2025
Start date
Mar 27, 2025
Primary completion
Nov 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion